Drugs

Nilotinib (1)

Pharmacogenomic Information   

DrugTherapeutic Area*Biomarker†Referenced
Subgroup
 Labeling Sections

Nilotinib (1)

Oncology 

BCR-ABL1 

Philadelphia chromosome positive 

Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specififc Populations, Clinical Pharmacology, Clinical Studies 

* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.

back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 04/20/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.